so Breezewood Acres on the IHUB board said that he had talked to friends (drs, Pharma folks, etc.) who said that the ongoing discussions were regarding the secondary endpoints. this would imply that we did not hit the primary endpoints. his post suggested that maybe we get an EUA for secondary, which I guess would be fine.

He's been a pretty solid poster - so I did pay attention to it, but was wondering if others had heard anything along these lines. at the end of the day, approval is approval - whether for secondary or primary endpoints I suppose - but it would make it more uncertain if we didn't nail the PE.